Surrozen Inc
Research Surrozen Inc (SRZN) on Bullrun: market cap USD 274.57M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSRZN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 274.57M
- Financial periodQ2 2026
- RevenueUSD 5.00M
- Net incomeUSD 50.18M
- Free cash flow-USD 7.43M
Valuation Snapshot
latest market cap is USD 274.57M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.48M | -USD 242.03M | -USD 30.37M | n/a | -32.37 | USD 89.25M | USD 6.64M | -USD 187.76M |
| FY2024 | USD 10.66M | -USD 63.56M | -USD 17.65M | n/a | -21.67 | USD 34.57M | USD 8.47M | -USD 21.38M |
| FY2023 | USD 0 | -USD 43.04M | -USD 40.76M | n/a | -21.33 | USD 36.04M | USD 3.38M | USD 37.94M |
| FY2022 | USD 12.50M | -USD 36.00M | -USD 44.87M | n/a | -15.56 | USD 24.69M | USD 6.62M | USD 76.00M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 274.57M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 220.90M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 46.81M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 19.16M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 17.31M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 225.62M | n/a | n/a | n/a |
About Surrozen Inc
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Surrozen Inc's market cap?
Surrozen Inc's market capitalization is USD 274.57M.
What does Surrozen Inc do?
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.